Last reviewed · How we verify

NCT06581471: TRICURE EU

The TRICURE EU Pivotal Study

Recruiting now NA Last updated 15 April 2026
What this trial tests

NA trial testing Transcatheter Tricuspid Valve Replacement in Tricuspid Valve Regurgitation in 80 participants. Currently enrolling.

Timeline
29 August 2024
Primary endpoint
30 October 2026
30 December 2030

Quick facts

Lead sponsorTRiCares
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment80
Start date29 August 2024
Primary completion30 October 2026
Estimated completion30 December 2030
Sites8 locations across Belgium, Germany

Drugs / interventions tested

Conditions studied

Sponsor

TRiCares

Who can join

18 and older, any sex, with Tricuspid Valve Regurgitation or Heart Valve Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Tricuspid valve edge to edge repair vs replacement - a comparative analysis and future directions.
    Hajj J, Kassab J, Zalaquett Z, Harb SC, et al · · 2026 · PMID 40779241 · DOI 10.1080/14796678.2025.2545133

Verify or expand the search:

Other trials of Transcatheter Tricuspid Valve Replacement

Trials testing the same drug.

Other recruiting trials for Tricuspid Valve Regurgitation

Currently open trials in the same condition.

Other TRiCares trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06581471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing